Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT03715621
- Brief Summary
Acute myeloid leukemia (AML) is a genetically heterogeneous disease and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option for AML except for AML-M3. Relapse remains the major cause of treatment failure after allo-HSCT. Molecular residual disease has been shown to be a strong risk factor for relapse after HSCT. In this study, the investigators will detect mutations before/after allo-HSCT by using next-generation sequencing (NGS) technique to measure residual disease and evaluate the prognostic impact of molecular residual disease in a cohort of AML participants receiving allo-HSCT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- 18 years or old;
- Clinical diagnosis of acute myeloid leukemia (AML);
- Availabe records of MICM and NGS results at diagnosis;
- Be going to receive allo-HSCT.
- Active malignancy;
- Pregnant or breast feeding women.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year relapse rate after allo-HSCT 1 year after allo-HSCT 1-year relapse rate after allo-HSCT
- Secondary Outcome Measures
Name Time Method 1-year recurrence-free survival (RFS) 1 year after allo-HSCT 1-year recurrence-free survival for AML participants
1-year overall survival (OS) 1 year after allo-HSCT 1-year overall survival (OS) for AML participants
Trial Locations
- Locations (1)
The First affiliated Hospital of SooChow University
🇨🇳Suzhou, Jiangsu, China